The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 29th 2025
At Asembia’s AXS25 Summit, Shea Hudson spotlighted how pharmacists are transforming into essential clinical partners through advanced technology, patient advocacy, and value-based collaboration.
Study Finds Link Between Tooth Loss and Cognitive Impairment, Dementia
July 8th 2021This risk was not seen in older adults with dentures, which could indicate that the cognitive decline associated with tooth loss could be mitigated through timely and effective treatment with dentures, according to the investigators.
Read More
Upadacitinib Meets Primary Endpoint of Clinical Remission in Patients with Ulcerative Colitis
July 8th 2021Study’s secondary endpoints were also met, including the achievement of endoscopic improvement, histologic-endoscopic mucosal improvement, and corticosteroid-free clinical remission at week 52.
Read More
Study: People Living with HIV/AIDS at Significantly Higher Risk of Suicide
July 8th 2021Despite significant medical advancements related to HIV treatment and quality of life, the risk of suicide in patients is high and health care providers should prioritize mental health screenings in this population.
Read More
Herpes Zoster Associated With Elevated Risk of Stroke, Cerebrovascular Events
July 8th 2021This risk decreased gradually according to age and length of time after an HZ episode, but epidemiological studies and the pathology of VZV vasculopathy both indicate that HZ is a key risk factor for stroke up to 1 year following an HZ episode.
Read More
Novel Biomarkers May Predict Likelihood, Timing of HIV Viral Rebound, Remission
July 7th 2021Investigators have identified metabolic and glycomic signatures in blood samples of post-treatment controllers, a rare population of HIV-infected individuals who can naturally sustain viral suppression after antiretroviral therapy.
Read More
Ohio Lottery Incentive Program Shows No Associated Increase In COVID-19 Vaccination Rates
July 7th 2021The study evaluated vaccination trends among adults aged 18 years or older using data from the CDC, comparing the rates in Ohio before and after the implementation of the lottery with states that did not have lottery programs.
Read More
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the results from the phase 3 trial evaluating an investigational 2 mg dose of semaglutide could change treatment options for patients with type 2 diabetes.
Watch
Assessing Adverse Events From Investigational Dose of Semaglutide Injection for Type 2 Diabetes
July 2nd 2021Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.
Watch
Efficacy, Safety of an Investigational Dose of Semaglutide Injection in Adults With Type 2 Diabetes
June 30th 2021Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.
Watch
Study: Eating Patterns Could Affect Risk of Heart Disease Mortality
June 30th 2021The research concluded that eating starchy snacks after meals and eating a Western-style lunch containing refined grains, cheese, and cured meat elevates the risk of dying from heart disease and other illnesses.
Read More
The Future of Pharmaceuticals and the FDA Pipeline
June 30th 2021Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, discusses upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.
Watch
Gilead Submits New Drug Application for Lenacapavir for the Treatment of HIV
June 30th 2021Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.
Read More
Key Events in the FDA Pipeline During COVID-19
June 29th 2021Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.
Watch